NYSE:IQV - Iqvia Stock Price, News, & Analysis

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) issued its quarterly earnings results on Monday, October, 22nd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.39 by $0.03. The medical research company had revenue of $2.59 billion for the quarter, compared to analyst estimates of $2.58 billion. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The company's revenue was up 5.2% on a year-over-year basis. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Iqvia.

Iqvia issued an update on its FY18 earnings guidance on Monday, October, 22nd. The company provided earnings per share guidance of $5.45-5.55 for the period, compared to the Thomson Reuters consensus estimate of $5.50. The company issued revenue guidance of $10.3-10.35 billion, compared to the consensus revenue estimate of $10.37 billion.Iqvia also updated its FY 2018 guidance to $5.45-5.55 EPS.

17 Wall Street analysts have issued 12-month price targets for Iqvia's shares. Their forecasts range from $112.00 to $150.00. On average, they expect Iqvia's share price to reach $135.40 in the next year. This suggests a possible upside of 8.9% from the stock's current price. View Analyst Price Targets for Iqvia.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 3 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

Media stories about IQV stock have trended very positive recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iqvia earned a media sentiment score of 3.7 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL) and Senomyx (SNMX).

Iqvia's stock is owned by a number of of institutional and retail investors. Top institutional investors include USS Investment Management Ltd (0.91%), DNB Asset Management AS (0.06%), Retirement Systems of Alabama (0.04%), Sheets Smith Wealth Management (0.03%), Gulf International Bank UK Ltd (0.02%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Dennis B Ph D Gillings, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks and Ronald A Rittenmeyer. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Gulf International Bank UK Ltd, Meeder Asset Management Inc., Beacon Financial Group, State of Alaska Department of Revenue, First Hawaiian Bank, Louisiana State Employees Retirement System and Oakbrook Investments LLC. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks and Ronald A Rittenmeyer. View Insider Buying and Selling for Iqvia.

IQV stock was purchased by a variety of institutional investors in the last quarter, including USS Investment Management Ltd, First Citizens Bank & Trust Co., Chesley Taft & Associates LLC, Altfest L J & Co. Inc., Steward Partners Investment Advisory LLC, Sheets Smith Wealth Management, CENTRAL TRUST Co and DNB Asset Management AS. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $124.33.

Iqvia has a market capitalization of $24.58 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. Iqvia employs 55,000 workers across the globe.

The official website for Iqvia is http://www.iqvia.com.

Iqvia's mailing address is 83 WOOSTER HEIGHTS ROAD, DANBURY CT, 06810. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]